Acute paralytic poliomyelitis, vaccine-associated
Chapter 1:Certain infectious and parasitic diseases
ICD-10 A80.4 is a billable code used to indicate a diagnosis of acute paralytic poliomyelitis, vaccine-associated.
Acute paralytic poliomyelitis, vaccine-associated, refers to a rare neurological condition that can occur following vaccination with live attenuated poliovirus vaccines, such as the oral polio vaccine (OPV). This condition is characterized by the sudden onset of muscle weakness and paralysis, which can affect various muscle groups, leading to significant morbidity. The vaccine-associated paralytic poliomyelitis (VAPP) occurs when the weakened virus in the vaccine reverts to a virulent form and causes disease in the vaccinated individual or in close contacts. Clinically, patients may present with symptoms such as fever, malaise, and muscle weakness, which can progress to flaccid paralysis. Diagnosis is primarily clinical, supported by the history of vaccination and the exclusion of other causes of acute flaccid paralysis. The incidence of VAPP is extremely low, especially in populations with high vaccination coverage, but it remains a critical consideration in public health and vaccination programs. Understanding the implications of vaccine-associated conditions is essential for healthcare providers, particularly in monitoring and reporting adverse events following immunization.
Detailed vaccination history, clinical presentation, and laboratory findings.
Patients presenting with acute flaccid paralysis following recent vaccination.
Consideration of differential diagnoses and reporting to public health authorities.
Neurological examination findings, imaging studies, and differential diagnosis considerations.
Patients with sudden onset of weakness and neurological deficits.
Need for thorough documentation to rule out other causes of paralysis.
When documenting vaccine administration and potential adverse effects.
Record of vaccine type, administration details, and any adverse reactions.
Infectious disease specialists should ensure accurate reporting of vaccine-related complications.
The incidence of VAPP is extremely low, estimated at approximately 1 in 2.4 million doses of the oral polio vaccine administered.
